Parkinson's Disease and Cancer: Mechanistic Insights and Therapeutic Opportunities From Cancer Neuroscience

There is a complex pathological association between neurodegenerative diseases and cancer. The epidemiological negative correlation between Parkinson's disease (PD) and brain tumor is particularly noteworthy. PD is characterized by the loss of dopaminergic neurons and the formation of Lewy bodies, while glioma, the representative of brain tumors, originates from the malignant transformation of glial cells. The molecular interaction network between these two diseases is elusive, limiting the development of cross‐disease treatment strategies. This review systematically summarizes the associations between PD and glioma in genetic predispositions, epigenetic modifications, alterations in subcellular compartments, and cellular mechanisms concerning neurons, glial cells, and stem cells. Additional links arise from circadian rhythm regulation, oxidative stress, and gut microbiota, underscoring the importance of systemic pathways that connect neurodegeneration and tumorigenesis. Within this context, cancer neuroscience emerges as a critical framework, demonstrating how neuronal activity drives cancer progression by shaping the tumor microenvironment. Therapeutic opportunities build upon these mechanistic insights, including engineering neuron types to suppress cancer growth, modulating synaptic genes, inducing neuronal cell death cascades, and controlling inflammation to disrupt tumor‐nerve crosstalk. Emerging neuroscience‐inspired technologies may drastically expand the treatment landscape. This review tries to unveil a potential theoretical paradigm for developing precise therapies with both neuroprotection and antitumor effects.

• Publication year

  2025

• Venue

  MedComm – Oncology

• Publication date

  2025-11-04

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1002/mog2.70044
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment

  2025cited by this paper
• Intervention strategies for Parkinson’s disease: the role of exercise and mitochondria

  2025cited by this paper
• CRISPRi-based screens in iAssembloids to elucidate neuron-glia interactions.

  2025cited by this paper
• Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells

  2025cited by this paper
• Hijacking of the nervous system in cancer: mechanism and therapeutic targets

  2025cited by this paper
• The Vital Role of Melatonin and Its Metabolites in the Neuroprotection and Retardation of Brain Aging

  2024cited by this paper
• Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity

  2024cited by this paper
• The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson’s disease

  2024cited by this paper
• Single-cell sequencing reveals glial cell involvement in development of neuropathic pain via myelin sheath lesion formation in the spinal cord

  2024cited by this paper
• APOBEC3 upregulation drives gemcitabine resistance

  2024cited by this paper
• Neurobiology of cancer: Adrenergic signaling and drug repurposing.

  2024cited by this paper
• Mesenchymal glioma stem cells trigger vasectasia—distinct neovascularization process stimulated by extracellular vesicles carrying EGFR

  2024cited by this paper
• Rugged fitness landscapes minimize promiscuity in the evolution of transcriptional repressors.

  2024cited by this paper
• Epigenetic regulation of tumor-immune symbiosis in glioma.

  2024cited by this paper
• Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing

  2024cited by this paper
• Protein mimetic 2D FAST rescues alpha synuclein aggregation mediated early and post disease Parkinson’s phenotypes

  2024cited by this paper
• The Role and Applied Value of Mitochondria in Glioma‐Related Research

  2024cited by this paper
• Advanced 3D imaging and organoid bioprinting for biomedical research and therapeutic applications.

  2024cited by this paper
• Glioblastoma cells increase expression of notch signaling and synaptic genes within infiltrated brain tissue

  2024cited by this paper
• Targeting the peripheral neural-tumour microenvironment for cancer therapy

  2024cited by this paper
• Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells

  2024cited by this paper
• Integrating priorities at the intersection of cancer and neuroscience.

  2024cited by this paper
• Ameliorating Mitochondrial Dysfunction for the Therapy of Parkinson's Disease.

  2024cited by this paper
• Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro.

  2024cited by this paper
• Alpha-Synuclein and Microglia in Parkinson’s Disease: From Pathogenesis to Therapeutic Prospects

  2024cited by this paper
• Cancer neuroscience at the brain–body interface

  2024cited by this paper
• Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression

  2024cited by this paper
• A knowledge graph approach to drug repurposing for Alzheimer's, Parkinson's and Glioma using drug-disease-gene associations

  2024cited by this paper
• Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease

  2023cited by this paper
• Glial Glutamate Transporter-Mediated Plasticity: System xc-/xCT/SLC7A11 and EAAT1/2 in Brain Diseases.

  2023cited by this paper
• IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression.

  2023cited by this paper
• Cancer neuroscience: State of the field, emerging directions.

  2023cited by this paper
• CRISPR/Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi.

  2023cited by this paper
• Astrocytic Chitinase‐3‐like protein 1 in neurological diseases: Potential roles and future perspectives

  2023cited by this paper
• Spatial Transcriptomics: Technical Aspects of Recent Developments and Their Applications in Neuroscience and Cancer Research

  2023cited by this paper
• Blood-Brain Barrier and Neurovascular Unit Dysfunction in Parkinson's Disease: From Clinical Insights to Pathogenic Mechanisms and Novel Therapeutic Approaches.

  2023cited by this paper
• Role of N6-methyladenosine modification in central nervous system diseases and related therapeutic agents.

  2023cited by this paper
• Targeting epigenetic modifications in Parkinson's disease therapy

  2023cited by this paper
• DNA Damage-Mediated Neurotoxicity in Parkinson’s Disease

  2023cited by this paper
• A new time dimension in the fight against metastasis.

  2023cited by this paper
• Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases

  2023cited by this paper
• Non-canonical NLRC4 inflammasomes in astrocytes contribute to glioma malignancy

  2023cited by this paper
• Interaction of tumor-associated microglia/macrophages and cancer stem cells in glioma.

  2023cited by this paper
• Oxidative Stress and Antioxidants in Neurodegenerative Disorders

  2023cited by this paper
• Cancer hallmarks intersect with neuroscience in the tumor microenvironment

  2023cited by this paper
• Transcriptome analysis reveals tumor microenvironment changes in glioblastoma.

  2023cited by this paper
• Autophagy and autophagy-related pathways in cancer

  2023cited by this paper
• Glioma synapses recruit mechanisms of adaptive plasticity

  2023cited by this paper
• Neuroinflammation is linked to dementia risk in Parkinson’s disease

  2023cited by this paper
• CRISPR/Cas9 Landscape: Current State and Future Perspectives

  2023cited by this paper
• Progress in circRNA-Targeted Therapy in Experimental Parkinson’s Disease

  2023cited by this paper
• Neuroprotective Effect of Melatonin on Sleep Disorders Associated with Parkinson’s Disease

  2023cited by this paper
• Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

  2023cited by this paper
• Glioblastoma revisited: from neuronal-like invasion to pacemaking.

  2023cited by this paper
• Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson’s disease

  2023cited by this paper
• NEAT1 enhances MPP+‐induced pyroptosis in a cell model of Parkinson's disease via targeting miR‐5047/YAF2 signaling

  2023cited by this paper
• Mitoferrin-1 Promotes Proliferation and Abrogates Protein Oxidation via the Glutathione Pathway in Glioblastoma

  2023cited by this paper
• Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson’s Disease

  2023cited by this paper
• Epigenetically modified AP-2α by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression

  2023cited by this paper
• The neuroscience of cancer

  2023cited by this paper
• The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson’s disease

  2023cited by this paper
• Human neural stem cells repress glioma cell progression in a paracrine manner by downregulating the Wnt/β‐catenin signalling pathway

  2023cited by this paper
• Epigenetic modification in Parkinson’s disease

  2023cited by this paper
• Inactivation of CACNA1H induces cell apoptosis by initiating endoplasmic reticulum stress in glioma

  2023cited by this paper
• Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation

  2023cited by this paper
• SNHG1, a KLF4‐upregulated gene, promotes glioma cell survival and tumorigenesis under endoplasmic reticulum stress by upregulating BIRC3 expression

  2023cited by this paper
• Parkinson’s Disease: A Narrative Review on Potential Molecular Mechanisms of Sleep Disturbances, REM Behavior Disorder, and Melatonin

  2023cited by this paper
• [Advances of glioma biomarkers].

  2023cited by this paper
• Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases

  2023cited by this paper
• Involvement of miRNA on Epigenetics landscape of Parkinson's disease: From pathogenesis to therapeutics.

  2023cited by this paper
• α-Synuclein-Induced Destabilized BMAL1 mRNA Leads to Circadian Rhythm Disruption in Parkinson’s Disease

  2023cited by this paper
• Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson’s disease

  2023cited by this paper
• Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy

  2023cited by this paper
• Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson’s disease

  2023cited by this paper
• lncRNA NEAT1: key player in neurodegenerative diseases.

  2023cited by this paper
• Evaluating the Genetic Role of Circadian Clock Genes in Parkinson’s Disease

  2023cited by this paper
• Cancer meets neuroscience: the association between glioma occurrence and intrinsic brain features

  2023cited by this paper
• Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma

  2023cited by this paper
• The Role of Hypoxia and Cancer Stem Cells in Development of Glioblastoma

  2023cited by this paper
• Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers

  2023cited by this paper
• Melatonin and 5-fluorouracil combination chemotherapy: opportunities and efficacy in cancer therapy

  2023cited by this paper
• Remote neuronal activity drives glioma progression through SEMA4F

  2023cited by this paper
• Role of Astrocytes in Parkinson’s Disease Associated with Genetic Mutations and Neurotoxicants

  2023cited by this paper
• Crif1 deficiency in dopamine neurons triggers early-onset parkinsonism

  2023cited by this paper
• Roles of lncRNAs in brain development and pathogenesis: Emerging therapeutic opportunities

  2023cited by this paper
• Neuro-immune interactions and immuno-oncology.

  2023cited by this paper
• GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity

  2023cited by this paper
• To metabolomics and beyond: a technological portfolio to investigate cancer metabolism

  2023cited by this paper
• Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models

  2023cited by this paper
• Exosomes rich in Wnt5 improved circadian rhythm dysfunction via enhanced PPARγ activity in the 6-hydroxydopamine model of Parkinson's disease.

  2023cited by this paper
• Potential functions and therapeutic implications of glioma-resident mesenchymal stem cells

  2023cited by this paper
• Black Pepper (Piper nigrum) Alleviates Oxidative Stress, Exerts Potential Anti-Glycation and Anti-AChE Activity: A Multitargeting Neuroprotective Agent against Neurodegenerative Diseases

  2023cited by this paper
• Exploring the Vital Link Between Glioma, Neuron, and Neural Activity in the Context of Invasion.

  2023cited by this paper
• Possible regulation of ganglioside GD3 synthase gene expression with DNA methylation in human glioma cells

  2023cited by this paper
• 3D bioprinting for organ and organoid models and disease modeling

  2023cited by this paper
• Staufen Impairs Autophagy in Neurodegeneration

  2022cited by this paper
• Autophagy is a novel pathway for neurofilament protein degradation in vivo

  2022cited by this paper
• Analysis of the m6A modification regulators in the substantia nigra and striatum of MPTP-induced Parkinson's disease mice.

  2022cited by this paper
• The N6-methyladenosine-mediated lncRNA WEE2-AS1 promotes glioblastoma progression by stabilizing RPN2

  2022cited by this paper
• Insights and opportunities at the crossroads of cancer and neuroscience

  2022cited by this paper

• No citing papers are available for this paper.